PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lung

Janzic, Urska; Kern, Izidor; Janzic, Andrej; Cavka, Luka; Cufer, Tanja

doi:10.1515/raon-2017-0037

Abstract

Background

With introduction of immunotherapy (IT) into the treatment of advanced non-small-cell lung cancer (NSCLC), a need for predictive biomarker became apparent. Programmed death ligand 1 (PD-L1) protein expression is most widely explored predictive marker for response to IT. We assessed PD-L1 expression in tumor cells (TC) and immune cells (IC) of squamous-cell carcinoma (SCC) and adenocarcinoma (AC) patients.

Patients and methods

We obtained 54 surgically resected tumor specimens and assessed PD-L1 expression by immunohistochemistry after staining them with antibody SP142 (Ventana, USA). Clinicopathological characteristics were acquired from the hospital registry database. Results were analyzed according to cut-off values of ≥ 5% and ≥ 10% of PD-L1 expression on either TC or IC.

Results

29 (54%) samples were AC and 25 (46%) were SCC. PD-L1 expression was significantly higher in TC of SCC compared to AC at both cut-off values (52% vs. 17%, p = 0.016 and 52% vs. 14%, p = 0.007, respectively) no difference in PD-L1 expression in IC of SCC and AC was found. In AC alone, PD-L1 expression was significantly higher in IC compared to TC at both cut-off values (72% vs. 17%, p < 0.001 and 41% vs. 14%, p = 0.008, respectively), while no significant difference between IC and TC PD-L1 expression was revealed in SCC.

Conclusions

Our results suggest a significantly higher PD-L1 expression in TC of SCC compared to AC, regardless of the cut-off value. PD-L1 expression in IC is high in both histological subtypes of NSCLC, and adds significantly to the overall positivity of AC but not SCC.

References

Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123-35. 10.1056/NEJMoa1504627
Open DOI Search in Google Scholar Back to article
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627-39. 10.1056/NEJMoa1507643
Open DOI Search in Google Scholar Back to article
Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387: 1540-50. 10.1016/S0140-6736(15)01281-7
Open DOI Search in Google Scholar Back to article
Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016; 387: 1837-46. 10.1016/S0140-6736(16)00587-0
Open DOI Search in Google Scholar Back to article
Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017; 389: 255-65. 10.1016/S0140-6736(16)32517-X
Open DOI Search in Google Scholar Back to article
Besse B, Johnson M, Janne PA, Garassino M, Eberhardt WEE, Peters S, et al. Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC). [abstract]. Eur J Cancer 2015; 51(Suppl 3),: abstr 16LBA, S717-18. 10.1016/S0959-8049(16)31938-4
Open DOI Search in Google Scholar Back to article
Reck M, Rodriguez-Abreu D, Robinson AG, Hui RN, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. New Engl J Med 2016; 375: 1823-33. 10.1056/Nejmoa1606774
Open DOI Search in Google Scholar Back to article
Socinski M, Creelan B, Horn L, Reck M, Paz-Ares L, Steins M, et al. CheckMate 026: A phase 3 trial of nivolumab vs investigator’s choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage IV/recurrent programmed death ligand 1 (PD-L1)-positive NSCLC. [abstract]. Ann Oncol 2016; 27(Suppl): abstr LBA7. 10.1093/annonc/ mdw435.39
Open DOI Search in Google Scholar Back to article
Kumar R, Collins D, Dolly S, McDonald F, O’Brien ME, Yap TA. Targeting the PD-1/PD-L1 axis in non-small cell lung cancer. Curr Probl Cancer 2017; 41: 111-24. 10.1016/j.currproblcancer.2016.12.002
Open DOI Search in Google Scholar Back to article
Califano R, Kerr K, Morgan RD, Lo Russo G, Garassino M, Morgillo F, et al. Immune checkpoint blockade: a new era for non-small cell lung cancer. Curr Oncol Rep 2016; 18: 59. 10.1007/s11912-016-0544-7
Open DOI Search in Google Scholar Back to article
Kerr KM, Tsao MS, Nicholson AG, Yatabe Y, Wistuba, II, Hirsch FR. Programmed death-ligand 1 immunohistochemistry in lung cancer: In what state is this art? J Thorac Oncol 2015; 10: 985-9. 10.1097/JTO.0000000000000526
Open DOI Search in Google Scholar Back to article
Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515: 563-7. 10.1038/nature14011
Open DOI Search in Google Scholar Back to article
Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thoracic Oncol 2017; 12: 208-22. 10.1016/j.jtho.2016.11.2228
Open DOI Search in Google Scholar Back to article
Scheel AH, Dietel M, Heukamp LC, Johrens K, Kirchner T, Reu S, et al. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Modern Pathol 2016; 29: 1165-72. 10.1038/ modpathol.2016.117
Open DOI Search in Google Scholar Back to article
McLaughlin J, Han G, Schalper K, Carvajal-Hausdorf D, Pelekanou V, Rehman J et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. Jama Oncol 2016; 2: 46-54. 10.1001/jamaoncol.2015.3638
Open DOI Search in Google Scholar Back to article
Ratcliffe MJ, Sharpe A, Midha A, Barker C, Scorer P, Walker J. A comparative study of PD-L1 diagnostic assays and the classification of patients as PD-L1 positive and PD-L1 negative. [abstract]. Cancer Res 2016; 76(Suppl): abstr LB-094. 10.1158/1538-7445.AM2016-LB-094
Open DOI Search in Google Scholar Back to article
Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348: 124-8. 10.1126/science.aaa1348
Open DOI Search in Google Scholar Back to article
Hellmann M, Rizvi N, Wolchok JD, Chan TA. Genomic profile, smoking, and response to anti-PD-1 therapy in non-small cell lung carcinoma. Mol Cell Oncol 2016; 3: e1048929. 10.1080/23723556.2015.1048929
Open DOI Search in Google Scholar Back to article
Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol 2016; 27: 147-53. 10.1093/annonc/mdv489
Open DOI Search in Google Scholar Back to article
Yang CY, Lin MW, Chang YL, Wu CT, Yang PC. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer 2014; 50: 1361-9. 10.1016/j.ejca.2014.01.018
Open DOI Search in Google Scholar Back to article
Yang CY, Lin MW, Chang YL, Wu CT, Yang PC. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma. Eur J Cancer 2016; 57: 91-103. 10.1016/j.ejca.2015.12.033
Open DOI Search in Google Scholar Back to article
D′Incecco A, Andreozzi M, Ludovini V, Rossi E, Capodanno A, Landi L, et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer 2015; 112: 95-102. 10.1038/bjc.2014.555
Open DOI Search in Google Scholar Back to article
Schmidt LH, Kummel A, Gorlich D, Mohr M, Brockling S, Mikesch JH, et al. PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups. PLoS One 2015; 10: e0136023. 10.1371/journal. pone.0136023
Open DOI Search in Google Scholar Back to article